Welcome to the Antimicrobial Chemotherapy Virtual Conference 2021

This conference is FREE OF CHARGE to attend

Register now

Jointly organised by the BSAC and GARDP. For 2021, the conference collaborators are the Helmholtz Institute for Pharmaceutical Sciences (HIPS), the German Center for Infection Research (DZIF) and the International Research Alliance for Antibiotic Discovery and Development (IRAADD) (a JPIAMR funded network)

Programme

Please note: All timings below are GMT

 

1300
Introductory remarks
Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP) - View Bio

SESSION ONE: KEYNOTE PRESENTATION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP)
1305
The politics of drug development
Dame Sally Davies, UK Government Special Envoy on Antimicrobial Resistance, UK Department of Health and Social Care - View Bio
1325
Q&A

1335
BREAK

SESSION TWO: Early Drug Discovery
Chair: Dr Marcus Miethke, Scientist & Project Manager, Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)
1345
In vitro and in vivo profiling of natural products from Myxobacteria towards the development of anti-infective drugs
Dr Jennifer Herrmann, Scientist, HIPS/HZI & DZIF - View Bio
1400
Screening libraries for novel chemical entities as a basis for drug development
Dr Benjamin Blasco Discovery Senior Project Manager, GARDP
1415
Microbial natural products: still an untapped source for novel antibiotic discovery
Dr Olga Genilloud, Scientific Director, Fundación MEDINA
1430
Q&A
All speakers

1440
BREAK

SESSION THREE: Pre-clinical antimicrobial development
Chair: tbc
1450
Adding old drugs to new
Dr Christopher Darlow, MRC Clinical Research Fellow, Institute of Systems, Molecular & Integrative Biology, University of Liverpool
1505
Linking PK and PD studies in animals with PBPK/PD modelling – in silico from mouse to human
Dr Katharina Rox, Postdoc, HZI/DZIF - View Bio
1520
Pre-clinical development of the natural compound antibiotic Corallopyronin A
Professor Achim Hoerauf, Institute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn/DZIF
1535
Q&A
All speakers

1545
BREAK

SESSION FOUR: POSTER SESSION
Chair: Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS)
1555 - 1630
6 posters will be presented followed by Q&A

1630
Day one closing remarks
Professor William Hope, University of Liverpool
1300
Introductory remarks
Professor William Hope, University of Liverpool - View Bio

SESSION FIVE: Learning lessons: clinical trials
Chair: Professor Mike Sharland, Consultant in paediatric infectious diseases, St George's University Hospitals NHS Foundation Trust
1305
What can we learn from COVID-19? The good and the bad of adaptive trials
Speaker tbc
1320
Innovative design of clinical trials
Professor Sarah Walker, University College London
1335
Developing a TB drug in academia: The BTZ043 from lead candidate to pivotal clinical trials – lesson learned from a complex endeavour
Speaker tbc
1350
Q&A
All speakers

1400
BREAK

SESSION SIX: Non-traditional approaches and challenges
Chair: tbc
1410
The non-traditional treatment pipeline (TBC)
Ursula Theuretzbacher, Founder, Center for Anti-Infective Agents (CEFAIA) - View Bio
1425
Elastase inhibitor
Dr Martin Everett, Chief Scientific Officer, Antabio - View Bio
1440
Harnessing immunological effectors
Speaker tbc
1455
Q&A
All speakers

1505
BREAK

SESSION SEVEN: KEYNOTE PRESENTATION
Chair: tbc
1515
Finance and science
Dr Patricia Bradford, Founder, Antimicrobial Development Specialists LLC, New York
1535
Q&A

1545
BREAK

SESSION EIGHT: PANEL DISCUSSION
Chair: Professor Laura JV Piddock, Director of Scientific Affairs, Global Antibiotic Research & Development Partnership (GARDP)
1555-1700
Careers in Drug Development and Antimicrobial Chemotherapy
Dr Olga Genilloud, Scientific Director, Fundación MEDINA
Sumathi Nambiar, Director, Division of Anti-Infective (DAI), FDA
Prof Dr Rolf Müller, Head of Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS) & Department Microbial Natural Products (MINS), Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS),
Dr Martin Everett, Chief Scientific Officer, Antabio

1700
Closing remarks
Professor Laura Piddock, Director of Scientific Affairs, GARDP - View Bio

Abstracts

Please submit your abstracts for consideration for Oral and Poster presentation at this meeting. Abstracts to be considered for Oral presentation must be submitted by 1700hrs GMT on Friday 11 December 2020 and abstracts to be considered for Poster presentation must be submitted by 1700hrs GMT on Friday 1 January 2021.

PLEASE NOTE: Those selected for Oral presentation must be available to present and join a live Q&A session on 2 February 2021 between 1555-1630hrs GMT.

Please download the submission information here and send to Esme Carruthers at ECarruthers@bsac.org.uk

Download

Alternatively you can submit your abstract by using the form below

    Lead Author Name
    Lead Author Contact Email
    Role and Organisation
    Presentation Preference (please select)
    Abstract Title
    Author Names and Organisations
    Structured Abstract (maximum word count 400 including graphs)

    Registration

    We encourage you to register, submit abstracts and join us in what promises to be another innovative and exciting conference.

    Registration is free of charge. For queries regarding registration, please contact Esme Carruthers at Ecarruthers@bsac.org.uk

    Please note that due to restrictions around COVID-19 this conference will be fully virtual.

    REGISTER NOW

    Having trouble finding what you're after?

    Top